Targeting residual cardiovascular risk & vascular calcification: The clinical perspective for BET inhibition10' education - July 3, 2019 - ERA-EDTA 2019 - Vincent Brandenburg, MD - Würselen, Germany
ERA-EDTA 2019 Epigenetics contribute to vascular calcification, which is a hallmark of CVD in CKD. Prof. Brandenburg explains how BET inhibition can interfere with factors and pathways associated with vascular calcification.
Video navigation menu
- CV risk in CKD - the magnitude of the problem 00:33
- CV risk factors in CKD and effect of standard CV therapy 03:47
- Vascular calcification in CKD is an active process 05:56
- Epigenetic changes in CKD and interfering with a BET-inhibitor 07:23
- Human evidenct of BET-inhibition: the BETonMACE trial 10:36
This lecture by prof. Vincent Brandenburg was part of a CME accredited symposium "Vascular calcification in kidney disease: Epigenetics as a novel approach?" held during ERA-EDTA 2019 in Budapest, Hungary.
Vincent Brandenburg, MD is head of the Division of Nephrology at the Rhein-Maas Klinikum in Würselen, Germany.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.